pMRX-IP-SECFP-Galectin3
(Plasmid
#64150)
-
PurposeExpression in mammalian cells (production of retrovirus vector)
-
Depositing Lab
-
Sequence Information
Full plasmid sequence is not available for this item.
Ordering
This material is available to academics and nonprofits only.
| Item | Catalog # | Description | Quantity | Price (USD) | |
|---|---|---|---|---|---|
| Plasmid | 64150 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 | |
Backbone
-
Vector backbonepMRX-IRES-puro
-
Vector typeMammalian Expression, Retroviral
-
Selectable markersPuromycin
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberUnknown
Gene/Insert
-
Gene/Insert nameGalectin3
-
Alt nameLGALS3
-
SpeciesH. sapiens (human)
-
Entrez GeneLGALS3 (a.k.a. CBP35, GAL3, GALBP, GALIG, L31, LGALS2, MAC2)
-
Tag
/ Fusion Protein
- SECFP (N terminal on insert)
Cloning Information
- Cloning method Unknown
- 5′ sequencing primer N/A (Common Sequencing Primers)
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
Depositor Comments
The pMRX-IP vector was kindly provided by Dr. Shoji Yamaoka (Tokyo Medical and Dental University, Tokyo, Japan) (Saitoh et al., J. Biol. Chem. 278, 36005-36012, 2003).
How to cite this plasmid
( Back to top)
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pMRX-IP-SECFP-Galectin3 was a gift from Tamotsu Yoshimori (Addgene plasmid # 64150 ; http://n2t.net/addgene:64150 ; RRID:Addgene_64150) -
For your References section:
Autophagy sequesters damaged lysosomes to control lysosomal biogenesis and kidney injury. Maejima I, Takahashi A, Omori H, Kimura T, Takabatake Y, Saitoh T, Yamamoto A, Hamasaki M, Noda T, Isaka Y, Yoshimori T. EMBO J. 2013 Aug 28;32(17):2336-47. doi: 10.1038/emboj.2013.171. Epub 2013 Aug 6. 10.1038/emboj.2013.171 PubMed 23921551